Feijie Xu

738 total citations · 1 hit paper
16 papers, 622 citations indexed

About

Feijie Xu is a scholar working on Molecular Biology, Organic Chemistry and Biomedical Engineering. According to data from OpenAlex, Feijie Xu has authored 16 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Organic Chemistry and 5 papers in Biomedical Engineering. Recurrent topics in Feijie Xu's work include Synthesis and biological activity (7 papers), Nanoplatforms for cancer theranostics (5 papers) and Cancer therapeutics and mechanisms (4 papers). Feijie Xu is often cited by papers focused on Synthesis and biological activity (7 papers), Nanoplatforms for cancer theranostics (5 papers) and Cancer therapeutics and mechanisms (4 papers). Feijie Xu collaborates with scholars based in China, Hong Kong and United Kingdom. Feijie Xu's co-authors include Jinyi Xu, Shengtao Xu, Zheying Zhu, Shuai Wen, Wenlong Li, Hequan Yao, Cong Ma, Honghao Sun, Hong Yao and Pui‐Chi Lo and has published in prestigious journals such as Angewandte Chemie International Edition, Nature Chemistry and Journal of Medicinal Chemistry.

In The Last Decade

Feijie Xu

16 papers receiving 618 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Near-infrared-activated anticancer platinum(IV) complexes directly photooxidize biomolecules in an oxygen-independent manner

2023 122 citations Zhiqin Deng, Huangcan Li et al. Nature Chemistry profile →

Peers

Countries citing papers authored by Feijie Xu

Since Specialization

Citations

This map shows the geographic impact of Feijie Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feijie Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feijie Xu more than expected).

Fields of papers citing papers by Feijie Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feijie Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feijie Xu. The network helps show where Feijie Xu may publish in the future.

Co-authorship network of co-authors of Feijie Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Feijie Xu. A scholar is included among the top collaborators of Feijie Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feijie Xu. Feijie Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Inducing Immunogenic Cancer Cell Death through Oxygen‐Economized Photodynamic Therapy with Nitric Oxide‐Releasing Photosensitizers 2024 ·Angewandte Chemie International Edition ·Feijie Xu, (unknown), (unknown), Kwan T. Chow, Pui‐Chi Lo	26
2	Copper-coordinated nanoassemblies based on photosensitizer-chemo prodrugs and checkpoint inhibitors for enhanced apoptosis-cuproptosis and immunotherapy 2023 ·Acta Biomaterialia ·Wenlong Liang, Chao Han, Danlu Zhang, Chunlei Liu, (unknown), Feijie Xu, Fang Cheng, Shuo Zhang, Chunzhao Liu, Yong‐Xin Li	27
3	Near-infrared-activated anticancer platinum(IV) complexes directly photooxidize biomolecules in an oxygen-independent manner breakdown → 2023 ·Nature Chemistry ·Zhiqin Deng, Huangcan Li, Shu Chen, Na Wang, Gongyuan Liu, Danjun Liu, (unknown), Feijie Xu, (unknown), Dangyuan Lei, Pui‐Chi Lo, (unknown), Jian Lü, Mengsu Yang, Ming‐Liang He, Guangyu Zhu	122
4	Cupric-ion-promoted fabrication of oxygen-replenishing nanotherapeutics for synergistic chemo and photodynamic therapy against tumor hypoxia 2023 ·Acta Biomaterialia ·(unknown), Feijie Xu, Yongxin Li, Honglin Jin, Pui‐Chi Lo	15
5	Supramolecular catalytic nanomedicines based on coordination self-assembly of amino acids for cascade-activated and -amplified synergetic cancer therapy 2022 ·Journal of Materials Chemistry B ·(unknown), Qiong Wu, (unknown), (unknown), Yanhui Zhang, Hao Geng, Chunlei Liu, Feijie Xu, Yongxin Li, Chunzhao Liu	8
6	Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors 2020 ·European Journal of Medicinal Chemistry ·Shuai Wen, Xinnan Li, Wenlong Li, Feijie Xu, (unknown), Hong Yao, Limei Yang, Huajian Zhu, Shengtao Xu, Zheying Zhu, Jinyi Xu	19
7	Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors 2019 ·European Journal of Medicinal Chemistry ·Hong Yao, Feijie Xu, Guangyu Wang, Shaowen Xie, Wenlong Li, Hequan Yao, Cong Ma, Zheying Zhu, Jinyi Xu, Shengtao Xu	26
8	Design, synthesis and biological evaluation of pyridine-chalcone derivatives as novel microtubule-destabilizing agents 2019 ·European Journal of Medicinal Chemistry ·Feijie Xu, Wenlong Li, Shuai Wen, Limei Yang, Yi Bi, Cong Ma, Hequan Yao, Shengtao Xu, Zheying Zhu, Jinyi Xu	53
9	Chemodivergent synthesis of N-(pyridin-2-yl)amides and 3-bromoimidazo[1,2-a]pyridines from α-bromoketones and 2-aminopyridines 2019 ·RSC Advances ·Yanpeng Liu, (unknown), Haipin Zhou, Feijie Xu, Cong Ma, Zhangjian Huang, Jinyi Xu, Shengtao Xu	22
10	Design, Synthesis and Molecular Modeling of Isothiochromanone Derivatives as Acetylcholinesterase Inhibitors 2019 ·Future Medicinal Chemistry ·Shuai Wen, Wenlong Li, Ying Yin, Limei Yang, Feijie Xu, Shengtao Xu, Hequan Yao, Zheying Zhu, Jinyi Xu	6
11	Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site 2018 ·European Journal of Medicinal Chemistry ·Wenlong Li, Shuai Wen, Honghao Sun, Feijie Xu, Yi Bi, Jinyi Xu, Cong Ma, Hequan Yao, Zheying Zhu, Shengtao Xu	76
12	Synthesis, molecular properties prediction and biological evaluation of indole-vinyl sulfone derivatives as novel tubulin polymerization inhibitors targeting the colchicine binding site 2018 ·Bioorganic Chemistry ·Wenlong Li, Honghao Sun, Feijie Xu, Shuai Wen, Jie Liu, Shengtao Xu, Hequan Yao, Cong Ma, Zheying Zhu, Jinyi Xu	37
13	Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain 2018 ·Bioorganic Chemistry ·Wenlong Li, Ying Yin, Shuai Wen, Feijie Xu, Hong Yao, Jie Liu, Keguang Cheng, Jinyi Xu, Zheying Zhu, Shengtao Xu	44
14	Discovery of Novel Quinoline–Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity 2018 ·Journal of Medicinal Chemistry ·Wenlong Li, Feijie Xu, Shuai Wen, Honghao Sun, Hong Yao, Cong Ma, Shengtao Xu, Hequan Yao, Zheying Zhu, Dong‐Hua Yang, Zhe‐Sheng Chen, Jinyi Xu	108
15	Concise Total Synthesis of (±)-Deguelin and (±)-Tephrosin Using a Vinyl Iodide as a Key Building Block 2018 ·Journal of Natural Products ·Shengtao Xu, Guangyu Wang, Feijie Xu, Wenlong Li, Aijun Lin, Hequan Yao, Jinyi Xu	13
16	Discovery of Novel 4-Arylisochromenes as Anticancer Agents Inhibiting Tubulin Polymerization 2018 ·ACS Medicinal Chemistry Letters ·Wenlong Li, Shuai Wen, Feijie Xu, Honghao Sun, Shengtao Xu, Hong Yao, Jie Liu, Hequan Yao, Zheying Zhu, Jinyi Xu	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact